☆ 4.7 Letter

Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy

LEUKEMIA (2020)

Get Full Text
Add to Collection

Journal

LEUKEMIA
Volume 34, Issue 11, Pages 3088-3090

Publisher

SPRINGERNATURE
DOI: 10.1038/s41375-020-0860-7

Keywords

-

Categories

Oncology Hematology

Funding

  1. Bristol-Myers Squibb K.K.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.